دورية أكاديمية
أعرض في EDS

Temporal and spatial modulation of the tumor and systemic immune response in the murine Gl261 glioma model.

التفاصيل البيبلوغرافية
العنوان: Temporal and spatial modulation of the tumor and systemic immune response in the murine Gl261 glioma model.
المؤلفون: McKelvey KJ; Bill Walsh Translational Cancer Research Laboratory, Kolling Institute, The University of Sydney Northern Clinical School and Northern Sydney Local Health District, St Leonards, NSW, Australia.; Sydney Vital Translational Research Centre, Royal North Shore Hospital, St Leonards, NSW, Australia.; The Brain Cancer Group, St Leonards, NSW, Australia., Hudson AL; Bill Walsh Translational Cancer Research Laboratory, Kolling Institute, The University of Sydney Northern Clinical School and Northern Sydney Local Health District, St Leonards, NSW, Australia.; Sydney Vital Translational Research Centre, Royal North Shore Hospital, St Leonards, NSW, Australia.; The Brain Cancer Group, St Leonards, NSW, Australia., Prasanna Kumar R; Bill Walsh Translational Cancer Research Laboratory, Kolling Institute, The University of Sydney Northern Clinical School and Northern Sydney Local Health District, St Leonards, NSW, Australia.; Sydney Vital Translational Research Centre, Royal North Shore Hospital, St Leonards, NSW, Australia., Wilmott JS; Melanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia.; Charles Perkins Centre, The University of Sydney, Camperdown, NSW, Australia., Attrill GH; Melanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia.; Charles Perkins Centre, The University of Sydney, Camperdown, NSW, Australia., Long GV; Melanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia.; Charles Perkins Centre, The University of Sydney, Camperdown, NSW, Australia.; Northern Sydney Cancer Centre, Royal North Shore Hospital, St Leonards, NSW, Australia.; Mater Hospital, North Sydney, NSW, Australia., Scolyer RA; Melanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia.; Charles Perkins Centre, The University of Sydney, Camperdown, NSW, Australia.; Royal Prince Alfred Hospital and New South Wales Health Pathology, Sydney, NSW, Australia., Clarke SJ; Bill Walsh Translational Cancer Research Laboratory, Kolling Institute, The University of Sydney Northern Clinical School and Northern Sydney Local Health District, St Leonards, NSW, Australia.; Sydney Vital Translational Research Centre, Royal North Shore Hospital, St Leonards, NSW, Australia.; Northern Sydney Cancer Centre, Royal North Shore Hospital, St Leonards, NSW, Australia., Wheeler HR; Bill Walsh Translational Cancer Research Laboratory, Kolling Institute, The University of Sydney Northern Clinical School and Northern Sydney Local Health District, St Leonards, NSW, Australia.; Sydney Vital Translational Research Centre, Royal North Shore Hospital, St Leonards, NSW, Australia.; The Brain Cancer Group, St Leonards, NSW, Australia.; Northern Sydney Cancer Centre, Royal North Shore Hospital, St Leonards, NSW, Australia., Diakos CI; Bill Walsh Translational Cancer Research Laboratory, Kolling Institute, The University of Sydney Northern Clinical School and Northern Sydney Local Health District, St Leonards, NSW, Australia.; Sydney Vital Translational Research Centre, Royal North Shore Hospital, St Leonards, NSW, Australia.; Northern Sydney Cancer Centre, Royal North Shore Hospital, St Leonards, NSW, Australia., Howell VM; Bill Walsh Translational Cancer Research Laboratory, Kolling Institute, The University of Sydney Northern Clinical School and Northern Sydney Local Health District, St Leonards, NSW, Australia.; Sydney Vital Translational Research Centre, Royal North Shore Hospital, St Leonards, NSW, Australia.; The Brain Cancer Group, St Leonards, NSW, Australia.
المصدر: PloS one [PLoS One] 2020 Apr 02; Vol. 15 (4), pp. e0226444. Date of Electronic Publication: 2020 Apr 02 (Print Publication: 2020).
نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't
اللغة: English
بيانات الدورية: Publisher: Public Library of Science Country of Publication: United States NLM ID: 101285081 Publication Model: eCollection Cited Medium: Internet ISSN: 1932-6203 (Electronic) Linking ISSN: 19326203 NLM ISO Abbreviation: PLoS One Subsets: MEDLINE
أسماء مطبوعة: Original Publication: San Francisco, CA : Public Library of Science
مواضيع طبية MeSH: Immunity, Innate*, Glioma/*immunology , Killer Cells, Natural/*immunology , T-Lymphocytes, Cytotoxic/*immunology, Animals ; Cell Lineage/immunology ; Cell Proliferation/genetics ; Chemokines/blood ; Chemokines/immunology ; Cytokines/blood ; Cytokines/immunology ; Disease Progression ; Flow Cytometry ; Glioma/blood ; Glioma/pathology ; Humans ; Killer Cells, Natural/metabolism ; Mice ; T-Lymphocytes, Cytotoxic/metabolism
مستخلص: Glioblastoma, the most aggressive form of glioma, has a 5-year survival rate of <5%. While radiation and immunotherapies are routinely studied in the murine Gl261 glioma model, little is known about its inherent immune response. This study quantifies the temporal and spatial localization of immune cell populations and mediators during glioma development. Eight-week old male C57Bl/6 mice were orthotopically inoculated with 1x106 Gl261 cells and tumor morphology, local and systemic immune cell populations, and plasma cytokines/chemokines assessed at day 0, 1, 3, 7, 14, and 21 post-inoculation by magnetic resonance imaging, chromogenic immunohistochemistry, multiplex immunofluorescent immunohistochemistry, flow cytometry and multiplex immunoassay respectively. From day 3 tumors were distinguishable with >30% Ki67 and increased tissue vascularization (p<0.05). Increasing tumor proliferation/malignancy and vascularization were associated with significant temporal changes in immune cell populations within the tumor (p<0.05) and systemic compartments (p = 0.02 to p<0.0001). Of note, at day 14 16/24 plasma cytokine/chemokines levels decreased coinciding with an increase in tumor cytotoxic T cells, natural killer and natural killer/T cells. Data derived provide baseline characterization of the local and systemic immune response during glioma development. They reveal that type II macrophages and myeloid-derived suppressor cells are more prevalent in tumors than regulatory T cells, highlighting these cell types for further therapeutic exploration.
Competing Interests: The authors have declared that no competing interests exist.
References: Gut. 2017 Jan;66(1):124-136. (PMID: 27402485)
Cancer Microenviron. 2013 Aug;6(2):159-67. (PMID: 23749739)
Front Oncol. 2018 Aug 13;8:314. (PMID: 30151353)
Cancer Res. 2016 Oct 1;76(19):5671-5682. (PMID: 27530322)
Am J Pathol. 2008 Aug;173(2):545-60. (PMID: 18599607)
J Neurol Sci. 1981 Jan;49(1):55-66. (PMID: 7205320)
Cancers (Basel). 2019 Feb 05;11(2):. (PMID: 30764570)
Neuro Oncol. 2012 Aug;14(8):979-93. (PMID: 22679124)
Brain Pathol. 2003 Jan;13(1):34-7. (PMID: 12580543)
Sci Rep. 2016 Mar 04;6:22477. (PMID: 26940435)
World Neurosurg. 2018 Dec;120:302-315. (PMID: 30196171)
Clin Cancer Res. 2018 Jun 1;24(11):2559-2573. (PMID: 29500275)
Cell Mol Life Sci. 2014 Oct;71(20):4007-26. (PMID: 25008045)
Int J Radiat Oncol Biol Phys. 2013 Jun 1;86(2):343-9. (PMID: 23462419)
Cell Rep. 2016 Dec 20;17(12):3219-3232. (PMID: 28009291)
Clin Cancer Res. 2017 Jan 1;23(1):124-136. (PMID: 27358487)
J Magn Reson Imaging. 2010 Aug;32(2):267-75. (PMID: 20677250)
Neurosurgery. 2015 Aug;62 Suppl 1:160-5. (PMID: 26181937)
Clin Cancer Res. 2006 Sep 15;12(18):5288-97. (PMID: 17000661)
Nat Rev Neurol. 2014 Jul;10(7):372-85. (PMID: 24912512)
Glia. 2017 Dec;65(12):1914-1926. (PMID: 28836293)
Mamm Genome. 2018 Dec;29(11-12):843-865. (PMID: 30178305)
Tomography. 2017 Mar;3(1):9-15. (PMID: 28553660)
Front Immunol. 2018 May 08;9:1004. (PMID: 29867979)
Neuro Oncol. 2018 Nov 12;20(12):1566-1572. (PMID: 29733389)
EMBO Mol Med. 2017 Dec;9(12):1629-1645. (PMID: 29038312)
J Transl Med. 2018 May 29;16(1):142. (PMID: 29843811)
Cancer Res. 1970 Sep;30(9):2401-13. (PMID: 5475484)
Neuropathology. 2016 Feb;36(1):39-49. (PMID: 26250788)
Front Neurol. 2017 Jun 23;8:296. (PMID: 28690586)
Biotechniques. 2012 Nov;53(5):305-9. (PMID: 23570046)
Front Immunol. 2018 Oct 31;9:2458. (PMID: 30429849)
Cancer Sci. 2006 Jun;97(6):546-53. (PMID: 16734735)
Br J Cancer. 2018 Nov;119(10):1171-1181. (PMID: 30393372)
Mamm Genome. 2018 Dec;29(11-12):806-816. (PMID: 30062485)
Proc Natl Acad Sci U S A. 2016 Mar 22;113(12):E1738-46. (PMID: 26884166)
Lab Invest. 2000 Jun;80(6):837-49. (PMID: 10879735)
J Microsc. 2011 Jun;242(3):262-78. (PMID: 21118252)
Biochim Biophys Acta. 2013 Aug;1836(1):158-65. (PMID: 23618720)
Nat Med. 2018 Sep;24(9):1459-1468. (PMID: 30104766)
Cancer Microenviron. 2011 Aug;4(2):209-17. (PMID: 21607751)
المشرفين على المادة: 0 (Chemokines)
0 (Cytokines)
تواريخ الأحداث: Date Created: 20200403 Date Completed: 20200706 Latest Revision: 20200706
رمز التحديث: 20240628
مُعرف محوري في PubMed: PMC7117758
DOI: 10.1371/journal.pone.0226444
PMID: 32240177
قاعدة البيانات: MEDLINE
الوصف
تدمد:1932-6203
DOI:10.1371/journal.pone.0226444